Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Inclusion Criteria: * 1.Male or female patients, age:≥18 years old. * 2.Confirmed by histology of recurrent or metastatic esophageal squamous cell carcinoma. * 3.Patients who undergo local or recurrent metastases after surgery and / or radiotherapy and chemotherapy,at least one measurable lesion(tumor lesions CT scan length ≥ 10 mm,lymph node lesions CT scan short diameter ≥ 15 mm,scan layer thickness is not greater than 6 mm). * 4.The ECOG physical status score: 0 to 2. * 5.Expected survival ≥ 3 months. * 6.Subjects received other treatment damage have been restored, which received nitroso or mitomycin interval ≥ 6 weeks; to accept other cytotoxic drugs, radiotherapy or surgery ≥ 4 weeks, and the wound has been completely healed; * 7.The main organs function properly: 1. blood routine examination standards to be met (14 days without blood transfusion and blood products): 1. HB≥90g/L; 2. ANC≥1.5×109/L; 3. PLT≥80×109/L; 2. biochemical tests to meet the following criteria: 1. TBIL\<1.5×ULN; 2. ALT and AST\<2.5×ULN, and \<5×ULN for patients with liver metastases 3. Serum Cr≤1.5×ULN or endogenous creatinine clearance\> 45ml/min (Cockcroft-Gault formula); * 8.The women of childbearing age must have taken reliable contraceptive measures or have a pregnancy test (serum or urine) within 7 days prior to enrollment and have a negative result and are willing to use the appropriate method at 8 weeks after the trial and the last given test contraception.For the man, consent should be given to appropriate contraception or surgical sterilization 8 weeks after the trial and at the last time the test drug was given; * 9.Patients should be voluntary to the trial and provide with signed informed consent Exclusion Criteria: * 1.Pregnant or lactating women; * 2.Patients with high blood pressure and who can not be reduced to normal range by antihypertensive therapy (systolic blood pressure\> 140 mmHg, diastolic blood pressure\> 90 mmHg) with myocardial infarction or myocardial infarction, arrhythmia and grade II heart Incomplete function; * 3.Have a significant impact on oral drug absorption factors, such as unable to swallow, chronic diarrhea and intestinal obstruction; * 4.Coagulation dysfunction(INR\>1.5 or prothrombin time (PT)\>ULN + 4 seconds or APTT\>1.5×ULN),with bleeding tendency or are receiving thrombolytic or anticoagulant therapy; * 5.with a clear gastrointestinal bleeding concerns (such as local active ulcer lesions, fecal occult blood + + above), 6 months of history of gastrointestinal bleeding; * 6.Central nervous system metastasis with symptoms; * 7.The investigator judged other circumstances that will affect the conduct of the study and the outcome of the study